Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of clinical pharmacology

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcph.298PMID 24691856PMCID PMC4396178
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration.

  2013influential reference
• Overcoming pharmacologic sanctuaries

  2013cited by this paper
• Novel Method To Assess Antiretroviral Target Trough Concentrations Using In Vitro Susceptibility Data

  2012cited by this paper
• Redefining the viral reservoirs that prevent HIV-1 eradication.

  2012cited by this paper
• Single- and Multiple-Dose Pharmacokinetics of Darunavir Plus Ritonavir and Etravirine in Semen and Rectal Tissue of HIV-Negative Men

  2012cited by this paper
• Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics

  2012cited by this paper
• Darunavir: a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection

  2012cited by this paper
• Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load

  2012cited by this paper
• HIV reservoirs and the possibility of a cure for HIV infection

  2011cited by this paper
• Within-Patient Atazanavir Trough Concentration Monitoring in HIV-1-Infected Patients

  2011cited by this paper
• Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.

  2011cited by this paper
• Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections

  2010cited by this paper
• Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

  2010cited by this paper
• HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

  2010cited by this paper
• Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

  2010cited by this paper
• HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications

  2010cited by this paper
• Comparative Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2 Test Using the TaqMan 48 Analyzer and the Abbott RealTime HIV-1 Assay

  2010cited by this paper
• Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

  2010cited by this paper
• Evaluation of an Upgraded Version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test for HIV-1 Load Quantification

  2010cited by this paper
• Influence of Alpha-1 Glycoprotein Acid Concentrations and Variants on Atazanavir Pharmacokinetics in HIV-Infected Patients Included in the ANRS 107 Trial

  2009cited by this paper
• Low atazanavir concentrations in cerebrospinal fluid

  2009cited by this paper
• Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1–Infected Individuals

  2009cited by this paper
• Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.

  2008cited by this paper
• Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

  2008cited by this paper
• Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free Fraction

  2008cited by this paper
• Effects of antiretroviral therapy on cognitive impairment

  2008cited by this paper
• Updated research nosology for HIV-associated neurocognitive disorders

  2007cited by this paper
• Quantitation of HIV-1 RNA levels in plasma and CSF of asymptomatic HIV-1 infected patients from South India using a TaqMan real time PCR assay.

  2007influential reference
• Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir

  2005cited by this paper
• Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1

  2004cited by this paper
• Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing Interval

  2004cited by this paper
• Protein Binding in Antiretroviral Therapies

  2003cited by this paper
• Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting

  2002cited by this paper
• Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.

  2001cited by this paper
• Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage.

  1997cited by this paper
• Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group.

  1997cited by this paper
• Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin.

  1996cited by this paper
• Clinical pharmacology: plasma protein binding of drugs.

  1981cited by this paper

• Pharmacokinetic approaches to standardize antiviral exposure in cerebrospinal fluid

  2025cites this paper
• Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation

  2024cites this paper
• Machine learning methods for developments of binding kinetic models in predicting protein‐ligand dissociation rate constants

  2023cites this paper
• Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies

  2023cites this paper
• In Silico Prediction of the Dissociation Rate Constants of Small Chemical Ligands by 3D-Grid-Based VolSurf Method

  2020cites this paper
• Pharmacologic approaches to HIV-associated neurocognitive disorders.

  2020cites this paper
• Combining biorelevant in vitro and in silico tools to investigate the in vivo performance of the amorphous solid dispersion formulation of etravirine in the fed state.

  2020cites this paper
• Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis

  2019cites this paper
• SMD-Based Interaction-Energy Fingerprints Can Predict Accurately the Dissociation Rate Constants of HIV-1 Protease Inhibitors

  2018cites this paper
• Darunavir concentrations in CSF of HIV‐infected individuals when boosted with cobicistat versus ritonavir

  2017cites this paper
• Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?

  2017cites this paper
• Evaluation of Cerebrospinal Fluid Virological Escape in Patients on Long-Term Protease Inhibitor Monotherapy

  2017cites this paper
• Metabolite Identification, Reaction Phenotyping, and Retrospective Drug-Drug Interaction Predictions of 17-Deacetylnorgestimate, the Active Component of the Oral Contraceptive Norgestimate

  2017cites this paper
• Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV‐1 protease inhibitor‐based regimens

  2016cites this paper
• Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients

  2016cites this paper
• Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals

  2016cites this paper
• Constructing Interconsistent, Reasonable, and Predictive Models for Both the Kinetic and Thermodynamic Properties of HIV-1 Protease Inhibitors

  2016cites this paper
• Sex Differences in Metabolism and Pharmacokinetics

  2015cites this paper
• Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients

  2015cites this paper
• Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System

  2014cites this paper